Global Hemorrhagic Stroke Treatment Market, By Treatment (Antihypertensives, Anticoagulants, Diuretics Anticonvulsants, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, homecare, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Hemorrhagic Stroke Treatment Market Analysis and Size
Every year, around 15 million human beings have stroke, out of which six million die and 5 million are left disabled permanently. This is essential as a result of the lack of knowledge and recollecting the stroke caution symptoms and symptoms. According to the American Heart Association/American Stroke Association (AHA/ASA), one in 3 Americans cannot remember the caution symptoms and symptoms of stroke. About 33% to 65% of people affected with intracerebral hemorrhage leads to death. Hemorrhagic stroke Treatment usually involves monitoring and lowering the blood pressure.
Data Bridge Market Research analyses a growth rate in the global hemorrhagic stroke treatment market in the forecast period 2022-2029. The expected CAGR of global hemorrhagic stroke treatment market is tend to be around 7.80% in the mentioned forecast period. The market was valued at USD 34 billion in 2021, and it would grow upto USD 62.01 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Hemorrhagic stroke treatment is also known as cerebral hemorrhage which is characterised by abnormally bleeding, caused by ruptured blood vessels inside the brain. Hemorrhagic stroke treatment generally involves monitoring and lowering the blood pressure. The hemorrhagic stroke treatment also consist of surgical intervention to lower the blood pressure. The hemorrhagic stroke treatment facilitates speedy recovery and eliminates further brain damage. The slight risk of surgical intervention in surrounding of the brain is achieved through the technique known as “burr hole” by hemorrhagic stroke treatment.
Hemorrhagic Stroke Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Antihypertensives, Anticoagulants, Diuretics Anticonvulsants, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, homecare, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland.), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Amorphex Therapeutics Holdings, Inc (U.S.), Bausch Health Companies Inc. (Canada)
|
|
Market Opportunities
|
|
Global Hemorrhagic Stroke Treatment Market Dynamics
Drivers
- Increased Prevalence of Stroke
Stroke is the 5th main cause of death with excessive occurrence price throughout the world due to the fact people are unaware of the preliminary symptoms and signs of stroke. Hence, governments of a few evolved nations, including the United States, Germany and the U.K, are taking sure projects in this direction. Some of such projects to deal with this trouble include STARS (Stroke Training and Awareness Resources), Act FAST, stroke software and cryogenic stroke awareness.
- Rise in Elderly Population
According to research, elderly population is more prone to suffer from this disease. According to the Aging World reports from 2015, there were approximately 562 million people 65 and older worldwide, which increased the disease's incidence and fueled the growth of the hemorrhagic stroke treatment market.
Opportunities
- Growing Incidence of Obesity
Obesity is a dominating factor in this regard. Around 60% canadians are obese and overweight and to prevent this developing epidemic, the Heart and Stroke Foundation has released the Target Obesity initiative. This initiative makes a speciality of stopping weight problems with the aid of using enhancing nutrients and bodily sports in Canada’s schools, communities, and workplaces. Hence, this will boost the market growth.
- Shorter Recovery Time
The main advantage of therapeutic based hemorrhagic stroke treatment is shorter onset of action and recovery time which results in higher survival of the patient. The shorter onset of action of hemorrhagic stroke therapeutic drugs is anticipated to boost the market. The growing prescription rate of antihypertensive drugs by physicians and high clinical effectiveness of hemorrhagic stroke treatment is expected to expand the market for hemorrhagic stroke treatment.
Restraints/Challenges
- Lack of skilled professionals
The lack of trained healthcare professionals who cannot use these devices could curb the growth of the global hemorrhagic stroke treatment market over a forecast period.
- High Generic Influx
The patent expiry of most of the drugs has surfaced the way for the entry of generics into the market. The extreme use of generic medicine can hamper the demand for branded drugs, thus affecting the market.
This global hemorrhagic stroke treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hemorrhagic stroke treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Hemorrhagic Stroke Treatment Market
COVID-19 left a major impact on the global hemorrhagic stroke treatment market. Our ongoing research is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included.
The Asian Stroke Advisory Panel (ASAP) performed a survey many of the member nations to discover the effect of COVID-19 on stroke care. The stroke admission numbers have fallen, as have the range of sufferers who obtained thrombolysis and mechanical thrombectomy. The stroke unit and rehabilitation beds were reallocated for COVID-19 care. The incidence of cerebrovascular events is, potentially, associated with a direct effect of the viral infection itself. Thus, it is essential to account for cerebrovascular events and cerebrovascular risk factors as critical components in the risk model for COVID-19 infection.
Global Hemorrhagic Stroke Treatment Market Scope
The global hemorrhagic stroke treatment market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Antihypertensives
- Thiazide-type diuretics
- Calcium channel blockers
- Anticoagulants
- Rivaroxaban
- Dabigatran
- Diuretics Anticonvulsants
- Acetazolamide
- Furosemide
- Thiazides
- Others
Route of Administration
- Oral
- Injectable
End-Users
- Hospitals
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Hemorrhagic Stroke Treatment Market Regional Analysis/Insights
The global hemorrhagic stroke treatment market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global hemorrhagic stroke treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is the dominating region due to the high demand for disease-specific treatment, the rise in adoption of newer technologies, and the presence of refined healthcare infrastructure.
Asia-Pacific is considered the growing region because of increased patient awareness level and high prevalence of bleeding disorders.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hemorrhagic Stroke Treatment Market Share Analysis
The global hemorrhagic stroke treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global hemorrhagic stroke treatment market
Key players operating in the global hemorrhagic stroke treatment market include:
- Novartis AG (Switzerland)
- Endo International Inc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
- Cipla Inc (India)
- Dr Reddy's Laboratories Ltd (India)
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc (U.S.)
- Zydus Group (India)
- Lupin (India)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Bausch Health Companies Inc. (Canada)
SKU-